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novirus vectors hold promise for use in gene transfer into a number 
of different issues as a means of performing ene therapy for 
genetic and acquired disorders. The advantages in using these 
vectors are the result of: (1) the wide variety of cell types that can 
be transduced invitro and in vivo; (2) the ability to ~oncentrate the 
vector to high titers of up to 10 I2 pfu/ml; (3) the fact that gene 
transfer occurs without he requirement ofcellular division and the 
viral genome does not integrate into the host chromosome. The 
distribution of vector DNA in tissues is dependent on the route of 
administration. Most of the virus is taken up by hcpatocytes when 
given by peripheral or portal vein infusion. In fact, in multiple 
animal models, 100% ofhepatocytes can be transduced with up to 
50 genome copies per cell. The vector can be delivered to the lungs, 
muscle, endothelial cells, and the central nervous system with 
relatively high efficiency. 
The excitement of using these vectors for gene therapy was 
tempered by a relatively short term of gene expression and the 
inability to transduce cells a second time in animal models. 
Interestingly, although the vector DNA does not integrate into the 
cell, vectors administered to mice deficient in antigen-dependent 
immunity have long-term persistence of over 10 months in some 
studies. Additionally, functional B and T cell deficiency allows for 
repeated transduction. 
Data from several groups using murine models ofgene therapy 
directed towards the lung and the liver have helped to elucidate thc 
nature of the immune responses limiting adenoviral-mediated g ne 
therapy. In sum, it appears that T cell-dependent, antigen-specific 
immunity limits the duration of transduced gene expression after 
inoculation of native animals, and largely prevents gene expression 
after secondary administration. Using mice with selective absence 
of CD8 or CD4 T ceils or B cells, it appears that (1) CD8 T cells 
play a predominant role in limiting the duration of gene expres- 
sion by eliminating transduced ceils or the transduced gene 
product, whereas CD4 T cells play a contributory role; and (2) 
CD4 T cells, by providing help to B cells, facilitate the production 
of neutralizing antibody in the serum and the airways, which 
precludes gene expression after secondary administration of the 
same or related adenoviral vectors. Based on a number of different 
studies, it appears that the CD8-mediated immune response is 
largely directed to newly synthesized viral gene products that are 
produced at low levels in the cells of the animals receiving the 
first generation viruses. 
There are two major approaches that will be needed to 
combat he immunologic response to the vector. The first is to 
produce a less antigenic vector. Advanced generation adenovirus 
vectors deleted for specific portions of the viral genome have been 
produced in different laboratories and are currently being tested 
in a variety of animal models. To date, some of these vectors 
include second-generation adenoviral vectors with E2 mutations, 
deletions, or deletions in the E4 region. Although the preliminary 
studies are not conclusive, they suggest that although these 
vectors may offer an improvement over the first-generation vec- 
tors as far as persistence of gene expression is concerned, the 
immune response will most likely limit the natural lifetime of 
vector DNA in host target tissues. Technical advances hould 
eventually lead to the production of a vector deleted of all viral 
genes. Although these types of vectors hould allow for maximal 
persistence of vector in transduced cells, the antibody response is
largely directed against virion proteins present in the vector coat; 
thus, even in the absence of viral protein synthesis, a humoral 
immune response will more than likely remain. Attenuation of the 
immune response would facilitate more prolonged gene expres- 
sion and minimize inflammation after initial vector administration 
and will most certainly be necessary if secondary gene transduc- 
tion is to be achieved. 
Immunomodulatory regimens used as adjunct herapy may be 
necessary to achieve long-term or repeat gene transfer. Conven- 
tional immunosuppressive agents, such as cyclosporin, have not 
proven effective in mitigating immune-mediated clearance of 
expression. Rather, some success has been achieved using cytoab- 
lative therapy. However, this approach results in untoward effects 
and is broadly immunosuppressive. In order to enhance gene 
expression, we have sought and obtained partial success in modi- 
fying the host response by selectively blocking the interactions of 
costimulatory ligands on T lymphocytes and antigen presenting 
ceils (APC), which play an important role in the initiation of an 
effective, antigen-specific immunologic response. Blockade of the 
costimulatory interactions between CD28 on T cells with B7 -1,-2 
on A,PC using soluble CTLA4Ig is one such example. Mice given 
soluble CTLA4Ig near the time of hepatic gene transfer with a 
first-generation recombinant adenovirus had persistent gene ex- 
pression for 6 months (length of experiment), whereas control 
animals had a fall-off of  gene expression within the first 2 to 
7 weeks. The mechanism by which CTLA4Ig prolonged adeno- 
virus-mediated gene expression was investigated by studying the 
T cell responses of recipients. Proliferation of splenic T cells in 
response to the adenovirus was evident in control animals that 
received the vector as early as day 11, but was absent or markedly 
reduced in animals that received CTLA4Ig. In agreement with the 
in vitro splenocyte assays, T cell infiltration into the livers of 
muCTLA4Ig treated mice was minimal and similar to that seen 
in mice not receMng adenovirus, whereas control mice that 
received adenovirus had robust infiltration of CD3, CD4, and 
CD8 positive cells. CTLA4Ig therapy resulted in a marked and 
significant reduction ofneutrafizing antibodies but did not totally 
ablate the response. Ongoing studies using other costimulatory 
blocking agents in combination with CTLA4Ig are in progress 
and demonstrate he ability to block humoral immunity as well 
in about 50% of treated mice. 
This type of therapy has several potential advantages over 
cytoablative therapy: (1) it results in transient immunosuppression; 
(2) it is not cytoablative and does not affect other ceils (e.g., 
neutrophils) involved in innate immune responses; (3) it has 
minimal effect on preexisting immunity; and (4) it is unlikely to 
result in immunologic tolerance to wild-type adenovirus. 
The theoretic ability to use recombinant adenovirus vectors as 
an efficient means of successfully performing gene transfer in 
human beings has been hampered by the resulting immunologic 
response against he vector. Although modifications of the vector 
are simple in concept, they are plagued with technical difficulties 
that have just begun to be overcome. Thus with the improvements 
in the vector and the possibility of using adjunct immunomodula- 
tion regimens, the next few years will be important for determining 
the suitability of these vectors for gene therapy relating to disorders 
requiring shorvterm, long-term, or repeat gene transfer for clinical 
gene therapy. 
Mark Kay, MD, PhD 
University of Washington 
Seattle, Wash. 
MODIF ICAT ION OF  VE IN  GRAFT 
ADAPTAT ION US ING ADENOVIRAL  VECTORS 
The devastating severity and epidemic proportions of arterial 
occlusive disease have made arterial bypass procedures among the 
most frequently performed operations. Ten years ago, 70,000 
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peripheral vascular and 150,000 aortocoronary bypass operations 
were performed annually.l.2 Use of the internal mammary artery as 
a bypass conduit for coronary artery bypass procedures yields 
superior patency compared to use of vein. Also, vein bypasses enjoy 
better esults than prosthetic grafts in most positions, especially in 
coronary and infrageniculate reconstructions, a Unfortunately, 
there is insufficient internal mammary artery for its exclusive use in 
heart surgery and for noncardiac needs. The lengthy and multifocal 
nature of atherosclerotic arterial esions necessitates u ing vein 
conduit. The normal anatomy of the greater saphenous vein, which 
is the most commonly used bypass conduit, is quite different from 
that of an artery. 4 There is no well-developed media in the vein, and 
there is no series of concentric elastic layers as are present in the 
artery. The thin-walled vein experiences a dramatic increase in wall 
tension with engraftment into the arterial circulation. The vein 
responds to the change in environment with wall-thickening 
characterized by smooth muscle proliferation and smooth muscle 
and extracdlular matrix accumulation. The vein graft wall thickens 
over time, resulting in a normalization of wall tension to a level 
observed in arteries across numerous pecies, '6 Starting as early as 
1 month after operation, autotogous vein grafts often suffer from 
stenosis and failure as a result ofintimal hyperplasia. 714 Accumu- 
lation of smooth muscle cells and extracelhilar matrix comprises the 
process ofintimal hyperplasia n the vein graft wall and around the 
graft-arterial nastomosis. Although vein graft atherosclerosis and 
progression of native arterial atherosclerosis cause vein graft failure, 
vein graft wall intimal hyperplasia can cause graft stenosis, and is 
a major cause of graft failure. 7,8,14 The proliferative lesions fea- 
turing predominantly smooth muscle cells account for failure in 
at least 25% of infrainguinal vein grafts 8,9 and 30% to 60% of 
aortocoronary vein grafts by 5 to 10 years, is If  the process 
becomes too far advanced, the affected graft may develop throm- 
bosis, resulting in a return of critical end organ ischemia. The 
morbidity and mortality rates from vein graft failure that is caused 
by intimal hyperplasia is a clinical problem of great importance, 
and one for which we currently have no effective prevention. 
Vein grafts often develop problems with luminal stenosis, 
leading to graft failure. The stenosis may be diffuse, but more often 
it is focal, with the remainder of the vein graft remaining without 
narrowing. The focal stenosis can proceed to occlusion, which 
damages or destroys the entire graft. Our goal is prevention of the 
focal luminal narrowing of the vein graft, not prevention of the 
adaptive wall thickening. 
Atherosclerosis, arterial wall biology, and the response of the 
artery to injury have all been studied more extensively than in vein 
grafts. Similarly, more work has been done in the setting of arterial 
gene transfer rather than with veins. The regulation of the vein graft 
wall remodeling process is not well understood, so selection of 
specific targets for genetic modification to improve the process is 
not obvious. To date, attention has focused on the use of two main 
methods for gene transfer and targets that involve regulation of 
smooth muscle proliferation. 
Adenoviral vectors have been used to genetically modify the 
vein graft wall before graft implantation. This was reported in a 
porcine vein graft model in the carotid circulation) 6 A replication- 
deficient adenovirus was used to introduce a lac Z reporter 
construct and also a soluble form ofVCAM-1, which competitively 
inhibits monocyte binding to endothelium. There was successful 
gene transfer for both molecules, with short periods of exposure of 
the vein ex vivo to concentrated virus. The lac Z gene transfer was 
mainly in the endothelium and also in the adventitia. 
DNA containing liposomes have also been used to effect gene 
transfer in veins before engraftment. H'VJ-liposomes with phos- 
phorothioate-oligodeoxynucleotides (ODNs) encoding antisense 
rat cdc2 kinase and antisense rat PGNA were used in a rabbit model 
of vein grafting in the carotid circulation. ~7 Temporary exposure of 
the vein segment before .grafting to the HVl-liposome ODN 
co[nplexes uccessfully achieved gene transfer and resulted in 
inhibition of the significant intimal thickening that is usually 
observed in the vein after engraftment. This represented an 
apparent shift in the vein graft adaptation from neointimal hyper- 
plasia to medial hyperplasia, which much more closely resembles 
arterial morphologic features. This included normalization of 
luminal radius-to-wall thiclmess ratio in the antisense-treated v in 
grafts compared with the carotid arterial control. High cholesterol 
diet treatment of the animals revealed that vein grafts treated with 
the antisense did not inhibit the accumulation of atherosclerotic 
plaques or foam cell lesions, which were common in the non- 
antisense-treated v in grafts. This suggested that the antisense cdc2 
and antisense PCNA treatment of the vein grafts before graft 
implantation conferred an effect of wall remodeling that involved 
medial thickening without as much intimal thickening, and that the 
vein graft wail was resistant to elevated cholesterol levels induced by 
diet, compared with controls. In addition, the antisense-treated 
vein grafts displayed enhanced endothelial nitric oxide synthase 
activity compared with controls and normal vein. The antisense- 
treated vein grafts also produced less snperoxide radical than did 
control grafts. They also used antisense ODN cationic lipid 
complexes inhuman saphenous veins ex vivo to assess gene transfer 
and achieved transfection of at least 75% of cells with significant 
biologic activity, is 
Other investigators, using the HVJ-liposome ODN method, 
have introduced the senescent cell-derived inhibitor 1 (Sdi-1) into 
vein grafts ex vivo before graft implantation i a similar abbit vein 
graft model. They observed that Sdi-1 gene transfer resulted in an 
inhibition of both the accumulation ofintimal cross-sectional area 
and smooth muscle cell proliferation compared with controls. In 
addition, Sdi-l- induced smooth muscle redifferentiation, com- 
pared with controls, as reflected by the pattern of expression of 
myosin heavy chain isoforms) 9 
We have used, ex vivo, adenoviral-mediated gene transfer in 
cryopreserved human saphenous veins derived from cadavers and 
have found that gene transfer efficiency ismaximal with higher viral 
titer, (1 x 10 l° pfu/ml),  with short-to-intermediate viral exposure 
ex vivo (2 to 4 hours), and with a mild intraluminai pressure 
elevation (80 mm Hg). 
With rabbit jugular veins ex vivo and adenovirus, we have 
observed that equal gene transfer occurs with incubation of 1 or 2 
hours and that longer incubations result in poorer or more sporadic 
gene transfer, possibly through toxicity. Moderate pressure (120 
mm Hg) is required to obtain gene transfer of medial smooth 
muscle cells, and the vector concentration appeared optimal at 
1 x 101° pfu/mi, as higher titers may result in toxicity. In vivo, high 
viral titers also result in toxicity. 
It is clear that effective gene transfer can be achieved in vein 
segments implanted in the arterial circulation and that more than 
one method of gene transfer can be used to accomplish this 
objective. The challenge that faces us at present is to define the 
specific genetic modification that will influence the vein graft 
adaptation process in a positive fashion and improve the clinical 
results of vein grafting in humans and resolve the method of gene 
transfer. 
Michael A. Golden, MD 
University of Pennsylvania 
Philadelphia, Pa. 
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CYTOSTAT IC  GENE TRANSFER FOR 
VASCULAR PROL IFERAT IVE  D ISORDERS 
Clinically significant restenosis remains the major complication of 
all percutaneous coronary revascularization procedures, occurring 
in 30% to 50% of patients within the first 6 months after revascu- 
latization. Although a number of factors contribute to restenosis, 
smooth muscle cell migration and proliferation and extracellular 
matrix deposition appear to be important pathophysiologic mecha- 
nisms. More than 30 different drugs and devices have been used in 
an attempt to prevent restenosis. This presentation utlines recent 
progress in using cytotoxic and cytostatic gene therapy for the 
prevention of restenosis. Recent work suggests that catheter- 
mediated elivery of replication-defective ad noviruses can be used 
to efficiently transduce medial vascular smooth muscle cells 
(VSMCs) after balloon angioplasty. Replication-defective ad novi- 
ruses encoding anonphosphorylatable, constituitively active form 
of the retinoblastoma gene (AdARb) and the herpes implex virus 
thymidine kinase gene (AdvTk) were constructed. Infection of 
primary rat aortic smooth muscle cells with AdARb completely 
inhibited growth factor-stimulated VSMC proliferation i  vitro. 
More importantly, AdkRb infection of balloominjured arterial 
segments reduced restenosis by 50% to 70% in the rat carotid and 
porcine iliofemoral models of balloon angioplasty. Safety studies 
demonstrated (1) no vascular inflammation, (2) no evidence of 
distant infection with AdkRb after local catheter delivery, and (3) 
no significant abnormalities of serum chemical composition or 
clotting parameters. Finally, infection with AdARb did not inhibit 
reendothelialization of the balloon-injured vessels. In a parallel set 
of experiments, infection of primary rat aortic smooth muscle cells 
with the AdvTK vector followed by ganciclovir treatment resulted 
in the efficient killing of proliferating cultured vascular smooth 
muscle cells in vitro. More importantly, infection with this vector 
followed by systemic ganciclovir t eatment resulted in 50% to 70% 
reductions in restenosis in both the rat carotid and porcine 
iliofemoral artery models of balloon angioplasty. There were no 
local or systemic toxicities associated with AdvTk plus ganciclovir 
therapy. In summary, catheter-mediated delivery of adenovirus 
vectors represents an efficient means of delivering recombinant 
genes to vascular smooth muscle cells at the site of balloon 
angioplasty. Both cytotoxic and cytostatic genes have been used to 
significantly reduce restenosis in two animal models of balloon 
angioplasty. Gene therapy holds promise as a safe and effective 
means of inhibiting restenosis after balloon angioplasty and other 
percutaneous revascularization procedures in human beings. 
Jeffrey M. Leiden, MD, PhD 
University of Chicago 
Chicago, Ill. 
MODIF ICAT ION OF  THE VASCULAR 
PHENOTYPE BY V IRAL  GENE TRANSFER:  
THERAPY AND TOXIC ITY  
Genetic modification of the vessel wall holds promise for the study 
of vascular pathophysiology and for the therapy of vascular disease. 
Using a variety of techniques, including viral and liposome- 
mediated gene transfer, specific genes may be introduced into 
vascular smooth muscle cells or endothelial cells to modify the 
vascular phenotype. Eventually such an approach may be clinically 
applied to artery or vein grafts, mechanically denuded vessels, or 
prosthetic grafts in the operative setting to prevent hrombosis, 
